查詢結果分析
來源資料
相關文獻
- 從大型流行病研究綜論糖尿病與冠心症
- The Effects of Glurenorm on Plasma Glucose and Lipids in Patients with Type 2 Diabetes Mellitus
- 糖尿病合併高血脂症之治療
- 糖尿病的大血管疾病
- 非胰島素依賴型糖尿病的高血脂症
- 脂倍坦對非胰島依賴型糖尿病人併高血脂症之療效
- Relationship between Several Surrogate Estimates of Insulin Sensitivity in Non-Diabetic Patients with Coronary Artery Disease
- The Antilipemic Effectiveness of Aluminium Clofibrate on Hyperlipidemic Patients with or without Diabetes Mellitus
- The hypolipidemic effect of gemfibrozil on hyperlipidemia in patients with non-insulin-dependent diabetes mellitus
- Metabolic Syndrome and Its Contribution to Coronary Artery Disease in Non-Diabetic Subjects
頁籤選單縮合
題 名 | 從大型流行病研究綜論糖尿病與冠心症=Diabetes Mellitus and Coronary Heart Disease Implications from Recent Epidemiological Studies |
---|---|
作 者 | 許惠恆; | 書刊名 | 內科學誌 |
卷 期 | 8:4 1997.12[民86.12] |
頁 次 | 頁156-161 |
分類號 | 412.9 |
關鍵詞 | 糖尿病; 高血脂症; 冠心症; Diabetes mellitus; Hyperlipidemia; Coronary heart disease; |
語 文 | 中文(Chinese) |
中文摘要 | 非胰島素依賴型糖尿病患罹患冠心症之機會比非糖尿病者增加,除了糖尿病本身 之因素,伴隨之血脂異常包括高三酸甘油脂血症(hypertriglyceridemia),高密度脂蛋白膽固 醇(HDL-C)過低亦非常重要。雖然糖尿病者之低密度脂蛋白膽白醇(LDL-C)與非糖尿 病者差不多,但糖尿病者之低密度脂蛋白顆粒較小,密度較實,可能比較容易被氧化及空透 血管壁形成血管粥狀硬化。 前瞻性流行病學研究發現,糖尿病者得冠心症之機會比非糖尿病者多出二倍以上。最近 數個大型之降血脂藥物流行病學研究指出,gemfibrozil(Helsinki Heart Study)、simvastatin(4S Study)及pravastatin(CARE)對糖尿病患者之血脂異常及冠心症的發生亦有一定的益處。 未來需要長期前瞻性專門針對糖尿病與冠心症之降血脂藥物試驗(如HMG CoA reductase inhibitor或fibrate類藥物),以瞭解這些藥物對糖尿病者冠心症之初級及次級預防 效果。 |
英文摘要 | Non insulin dependent diabetes melitus (NIDDM) is associated with a marked increase in coronary heart disease (CHD). Reasons for the increased CHD risk in NIDDM are multifactorial, however, diabetes and accompanying dyslipidemia certainly play an important role. Subjects with NIDDM have increased triglyceride levels and decreased HDL colesterol levels relative to those nondiabetic subjects. Although the absolute concentration of LDL cholesterol is similar in NIDDM and normoglycemic subjects, those with NIDDM have more small-dense LDL than nondiabetic subjects. Recent observations from several prospective, double blinded epidemiological studies indicated that diabetes patients have two more risk of CHD than nondiabetic individuals. Treatment with HMG CoA reductase inhibitor (simvastatin or pravastatin) effectively decreased total cholesterol, LDL cholesterol, triglyveride levels while increased HDL cholesterol concentrations both in diabetic and nondiabetic subjects. Treatment of dyslipidemia in diabetic subjects significantly decreases the risk of CHD, at least equal to or more than those of nondiabetic subjects. Further large scale prospective epidemiological study specifically for diabetic patients are necessary. In addition, trials with HMG CoA reductase and/or fibric acid to study the primary prevention or secondary prevention of CHD in NIDDM subjects are also important. |
本系統中英文摘要資訊取自各篇刊載內容。